Niklas Anzinger

What Niklas talked about

Niklas Anzinger works on Prospera, a special economic zone in Honduras with its own legal and governance system modeled on common law, which he compares to the development trajectories of Hong Kong or Singapore. Within Prospera, he is building Infinita City, a biotech district meant to draw entrepreneurs and scientists working on gene therapies and other treatments not yet approved by the FDA.

He argued that regulatory delay, rather than a lack of scientific readiness, is the main reason treatments like GLP-1 drugs and mRNA vaccines took decades to reach patients. He pointed to right-to-try laws and jurisdictions like Prospera as routes for patients to access unapproved-but-safe therapies outside the slower pace of institutions like the FDA, citing gene therapies offered in Prospera, including one that reportedly cost $25,000 versus the $500,000-$1 million typical of gene therapies approved in the US.

The show

The Total Entrepreneur is a weekly conversation with founders, researchers, and health experts about what actually moves entrepreneurial performance across mind, body, spirit, and business.